Inventor · disambiguated record
Alexander Gutin
Also filed as: GUTIN ALEXANDER
28 granted patents·52 pending applications·74 citations·filing 2006–2025
95Inventor score
Files withMYRIAD GENETICS INC63MYRIAD MYPATH LLC5LABORATORY CORP AMERICA HOLDINGS3STONE STEVEN3ABKEVICH VICTOR2
Top patents by PatentIndex Score
80 records- 0195US12221656B2Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2022·Granted Feb 11, 2025·3 cites·18 claims
- 0293US9574229B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2016·Granted Feb 21, 2017·11 cites·41 claims
- 0393US9279156B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2013·Granted Mar 8, 2016·16 cites·18 claims
- 0491US11834719B2Genes and gene signatures for diagnosis and treatement of melanomaMYRIAD MYPATH LLC·Filed 2021·Granted Dec 5, 2023·3 cites·17 claims
- 0590US10876164B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2015·Granted Dec 29, 2020·5 cites·4 claims
- 0689US11584967B2Genes and gene signatures for diagnosis and treatment of melanomaMYRIAD MYPATH LLC·Filed 2020·Granted Feb 21, 2023·3 cites·18 claims
- 0789US11174517B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2016·Granted Nov 16, 2021·4 cites·7 claims
- 0889US9976188B2Cancer biomarkersMYRIAD GENETICS INC·Filed 2017·Granted May 22, 2018·5 cites·8 claims
- 0988US10954568B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2015·Granted Mar 23, 2021·3 cites·4 claims
- 1088US2024182979A1Cancer biomarkersMYRIAD GENETICS INC·Filed 2024·Application pending·0 cites
- 1187US10626449B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2017·Granted Apr 21, 2020·2 cites·13 claims
- 1286US11505832B2Method of using biomarkers and clinical variables for predicting chemotherapy benefitMYRIAD GENETICS INC·Filed 2020·Granted Nov 22, 2022·2 cites·20 claims
- 1386US10612098B2Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2016·Granted Apr 7, 2020·2 cites·15 claims
- 1484US9605319B2Gene signatures for cancer diagnosis and prognosisSTONE STEVEN·Filed 2011·Granted Mar 28, 2017·6 cites·8 claims
- 1583US11225685B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2020·Granted Jan 18, 2022·1 cites·20 claims
- 1682US12371750B2Genes and gene signatures for diagnosis and treatment of melanomaMYRIAD MYPATH LLC·Filed 2023·Granted Jul 29, 2025·0 cites·14 claims
- 1781US2023111438A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 1880US9388472B2Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2014·Granted Jul 12, 2016·3 cites·36 claims
- 1980US2025250643A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
- 2079US10519513B2Cancer BiomarkersMYRIAD GENETICS INC·Filed 2019·Granted Dec 31, 2019·1 cites·8 claims
- 2178US11174519B2Method of treating cancerMYRIAD GENETICS INC·Filed 2019·Granted Nov 16, 2021·0 cites·11 claims
- 2278US11021752B2Genes and gene signatures for diagnosis and treatment of melanomaMYRIAD GENETICS INC·Filed 2014·Granted Jun 1, 2021·1 cites·10 claims
- 2378US10612099B2Genes and gene signatures for diagnosis and treatment of melanomaMYRIAD GENETICS INC·Filed 2016·Granted Apr 7, 2020·1 cites·5 claims
- 2478US2022205046A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2021·Application pending·0 cites
- 2578US2022259675A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 2677US2025215509A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
- 2776US10851425B2Method for treating cancerMYRIAD GENETICS INC·Filed 2019·Granted Dec 1, 2020·0 cites·13 claims
- 2876US2025223655A1Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
- 2976US2024282407A1Electronic variant classificationMYRIAD GENETICS INC·Filed 2024·Application pending·0 cites
- 3076US2022205022A1Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2021·Application pending·0 cites
- 3176US2021310079A1Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2021·Application pending·0 cites
- 3275US2020399713A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2020·Application pending·0 cites
- 3374US10400287B2Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2017·Granted Sep 3, 2019·1 cites·6 claims
- 3473US2023340615A1Genes and gene signatures for diagnosis and treatment of melanomaMYRIAD MYPATH LLC·Filed 2023·Application pending·0 cites
- 3573US2025179587A1Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
- 3672US12421555B2Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2018·Granted Sep 23, 2025·0 cites·10 claims
- 3772US12180551B2Method of using biomarkers and clinical variables for predicting chemotherapy benefitMYRIAD GENETICS INC·Filed 2022·Granted Dec 31, 2024·0 cites·20 claims
- 3871US7662566B2Gene copy number profilingMYRIAD GENETICS INC·Filed 2007·Granted Feb 16, 2010·1 cites·7 claims
- 3970US2018334722A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2018·Application pending·0 cites
- 4069US2020056246A1Cancer biomarkersMYRIAD GENETICS INC·Filed 2019·Application pending·0 cites
- 4167US10501807B2Cancer biomarkersMYRIAD GENETICS INC·Filed 2018·Granted Dec 10, 2019·0 cites·8 claims
- 4266US2022112565A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2021·Application pending·0 cites
- 4365US2015080260A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2014·Application pending·0 cites
- 4464US2022243275A1Genes and gene signature for diagnosis and treatment of melanomaMYRIAD MYPATH LLC·Filed 2021·Application pending·0 cites
- 4564US2025347703A1Adjusted multi-biomarker disease activity score for inflammatory disease assessmentLABORATORY CORP AMERICA HOLDINGS·Filed 2025·Application pending·0 cites
- 4663US2023212653A1Methods and materials for assessing homologous recombination deficiency in breast cancer subtypesMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 4762US2021071269A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2020·Application pending·0 cites
- 4862US2014278135A1Electronic variant classificationMYRIAD GENETICS INC·Filed 2014·Application pending·0 cites
- 4961US2014170139A1Hypoxia-related gene signatures for cancer classificationMYRIAD GENETICS INC·Filed 2014·Application pending·0 cites
- 5060US2014363521A1Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2014·Application pending·0 cites
Showing the top 50 of 80 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Alexander Gutin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →